FindTrial
Sign In

Study on the Value of SWE-Based Liver and Spleen Stiffness Combined with Platelet Count and Serum Vascular Endothelial Growth Factor Levels in Evaluating Esophageal Varices in Patients with Liver Cirrhosis

Study on the Value of SWE-Based Liver and Spleen Stiffness Combined with Platelet Count and Serum Vascular Endothelial Growth Factor Levels in Evaluating Esophageal Varices in Patients with Liver Cirrhosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600129563
Enrollment
Unknown
Registered
2026-08-06
Start date
2026-08-06
Completion date
Unknown
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Cirrhosis

Interventions

Gold Standard:Gold standard for PLT: automated hematology analyzer Gold standard for VEGF: enzyme-linked immunosorbent assay (ELISA)
Index test:Index test for PLT: Platelet count was determined by automated hematology analyzer. Index test for VEGF: Serum vascular endothelial growth factor concentration was measured by enzyme-linked

Sponsors

Rugao People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
37 Years to 77 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for liver cirrhosis; 2. No history of esophageal variceal bleeding (EVB); 3. Aged between 37 and 77 years old.

Exclusion criteria

Exclusion criteria: 1. Complicated with hepatocellular carcinoma or other malignant tumors; 2. Co-infection with other hepatotropic viruses; 3. Presence of hematological diseases; 4. History of splenectomy.

Design outcomes

Primary

MeasureTime frame
PLT;VEGF;Accuracy;—

Secondary

MeasureTime frame
Sensitivity;Specificity;—

Countries

China

Contacts

Public ContactZhang Han

Rugao People's Hospital

zhh961128@163.com+86 159 9660 8092

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 25, 2026